Recommendation ID
There is a need for additional research on the management of bleeds that occur while people are receiving apixaban, rivaroxaban or dabigatran etexilate, as there are no antidotes or established treatments to stop active bleeding for these agents.
Any explanatory notes
(if applicable)

Source guidance details

Comes from guidance
Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
Date issued
February 2013

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 27/02/2013